Cellino and Matricelf (TASE: MTLF) Forge Global Partnership to Advance Personalized Spinal Cord Injury Treatments

In a landmark collaboration, Cellino andMatricelf today unveiled a strategic alliance to accelerate the globalbiomanufacturing of personalized therapies for spinal cord injuries. Byintegrating Cellino’s cutting-edge Nebula™ automated biomanufacturing systemwith Matricelf’s proprietary double autologous 3D differentiation technology,the partnership aims to revolutionize regenerative medicine, enabling scalable,patient-specific treatments for neurological disorders.

Credits:Business Wire

Nebula™: A Breakthrough in iPSCProduction
Cellino’s proprietary closed-cassette Nebula™ system represents a paradigmshift in induced pluripotent stem cell (iPSC) manufacturing. Designed foron-demand, contamination-free production at industrial scale, the platformdelivers unprecedented consistency and sterility, bridging a critical gapbetween laboratory innovation and clinical application.

A Milestone in Autologous TherapyDevelopment
As a pivotal achievement, Cellino successfully produced and deliveredautologous iPSC lines from four donors to Matricelf—a biotech pioneerdeveloping regenerative therapies for spinal cord injury. Matricelf’s novelapproach leverages a patient-derived extracellular matrix hydrogel from omentaltissue, creating a bioactive scaffold that drives precise neuraldifferentiation and tissue formation without immunosuppression.

Functional Neural Tissues: A Validationof Innovation
Matricelf has now engineered functional neural tissues from Cellino-generatediPSCs, demonstrating synchronized electrical activity—a critical indicator ofviable neural networks. Rigorous testing confirmed the tissues’ neuralidentity, with genetic and protein marker expression matching industrybenchmarks and aligning with Matricelf’s proprietary iPSC-derived controls.

Clinical Pathway: Targeting Unmet Needs
Building on this progress, Matricelf plans to submit an Investigational NewDrug (IND) application in 2024, advancing its autologous iPSC therapy intoclinical trials. This transformative approach addresses a critical void inspinal cord injury care, offering potential functional restoration for millionsworldwide.

Leadership Perspectives
“This international collaboration is a cornerstone in our mission to deliverfully autologous regenerative therapies for spinal cord injury,” said GilHakim, CEO of Matricelf. “By merging Matricelf’s tissue engineering expertisewith Cellino’s scalable biomanufacturing, we’re setting a new benchmark forpatient-specific therapies.”

Dr. Marinna Madrid, Co-Founder and ChiefProduct Officer of Cellino, added, “The ability to produce high-quality,patient-specific iPSCs at scale is a game-changer for regenerative medicine.Our partnership with Matricelf exemplifies how global innovation can accelerateaccess to life-altering therapies.”

The alliance underscores both companies’commitment to harnessing AI-driven automation, high-throughputbiomanufacturing, and advanced neural engineering. Together, they aim tocommercialize next-generation regenerative therapies, redefining treatment standardsfor neurological diseases and expanding global access to transformative care.